New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative ...
-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo --
Source: eagletribune.com
📰 Simultaneously Published News
Simultaneously Published News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Simultaneously Published. Real-time updates on events, politics, business and more.
AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of investigational olpasiran (formerly AMG 890)...
Source: prnewswire.com
NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today presented new compelling data from the Phase 3 FOURIER open label extension (OLE) studies of Repatha® (evolocumab) in...
Puerto Rico Comunidad Autonoma De Cataluna Michael Strapazon Jessica Akopyan Amgen Medinfo Kyowa Kirin Co Ltd
Source: prnewswire.com
NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS - Press Release
Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death80% of Patients Achieved Guideline Directed LDL-C L
Puerto Rico Comunidad Autonoma De Cataluna Michael Strapazon Jessica Akopyan Amgen Medinfo Kyowa Kirin Co Ltd
Source: wiredprnews.com